Academic Journals Database
Disseminating quality controlled scientific knowledge

Hemoglobin subunit beta (HBB) is a potential biomarker for predicting response to Gefitinib in NSCLC patients

ADD TO MY LIST
 
Author(s): Poh Kuan Chong | Huiyin Lee | Marie Chiew Shia Loh | Wan-Teck Lim | Siew Pang Chan | Ross Andrew Soo | Yoon Pin Lim

Journal: Journal of Integrated OMICS
ISSN 2182-0287

Volume: 1;
Issue: 2;
Start page: 298;
Date: 2011;
Original page

Keywords: NSCLC | Plasma | Proteomics | Gefitinib | iTRAQ | HBB

ABSTRACT
EGFR mutation status has been reported to correlate well with the response of NSCLC patients to Gefitinib. However, EGFR mutation analysis is invasive in nature and recent studies supported the notion that EGFR mutation was unable to predict response to Gefitinib in some patients. We therefore conducted plasma proteomics to identify potential biomarkers that are less invasive and whose expressions correlate more significantly to response to Gefitinib. To identify protein candidates that correlate with response to Gefitinib, we profiled the relative expression levels of plasma proteins between responders and non-responders prior to Gefitinib treatment. Relative quantification of plasma proteins were analysed using Isobaric Tags for Relative and Absolute Quantification (iTRAQ) and liquid chromatography-electrospray ionization (ESI) tandem mass spectrometry. Proteins that were commonly upregulated or downregulated amongst responders but not the non-responders were selected for validation via immunoblotting. HBB protein was found to be significantly under-expressed in the plasma samples from 6 out of 7 gefitinib-responsive patients but over-expressed in a majority of the non-responders. Our finding showed that HBB is a potential biomarker for predicting response to Gefitinib that may be subject to a larger study to examine its role as a companion biomarker for Gefitinib therapy.
Save time & money - Smart Internet Solutions      Why do you need a reservation system?